Drug survival is a real-life reflection of drug performance in routine medical practice and measures the patient's persistence under a given treatment. Survival of systemic treatment of atopic dermatitis (AD) has been evaluated in previous analyses in routine clinical practice. Recently, dupilumab, a fully human monoclonal antibody that targets the IL-4 receptor α, has been approved for the treatment of moderate to severe AD.

Get PDF with LibKey

View the article @ The British journal of dermatology (sign-in may be required)